Patents Assigned to Ascensia Diabetes Care Holdings AG
  • Patent number: 9982289
    Abstract: A test strip or electrochemical sensor for measuring the amount of an analyte in a biological fluid, e.g. the glucose content of whole blood, includes a size self-limiting reagent formulation employing an enzyme system for reaction with the analyte, the reactive system mixed into a water-soluble swellable polymer matrix containing small water-insoluble particles having a nominal size of about 0.05 to 20 ?m, preferably about 1 to 10 ?m. The weight ratio of the water-insoluble particles to the water-soluble swellable polymer matrix is about 1/2 to 2/1. The reagent formulation is deposited onto a non-porous substrate to form a thin layer about 6-16 ?m thick, providing a rapid and stable response to application of a sample, while being insensitive to the amount of the sample.
    Type: Grant
    Filed: May 11, 2011
    Date of Patent: May 29, 2018
    Assignee: ASCENSIA DIABETES CARE HOLDINGS AG
    Inventor: Karen L. Marfurt
  • Patent number: 9983341
    Abstract: Apparatus for illuminating one or more components of an electronic device having a visual display (e.g., a backlit display), such as one or more keys of keyboards, one or more interface ports, or one or more external surfaces are disclosed. In one or more embodiments, a component illumination apparatus has a visual display and a light guide optically coupled to the visual display and that is adapted to illuminate one or more components external to the visual display. Methods of component illumination and illumination systems are described, as are other embodiments.
    Type: Grant
    Filed: May 27, 2015
    Date of Patent: May 29, 2018
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventor: Eugene Prais
  • Patent number: 9958410
    Abstract: Biosensor system measurement devices used to determine the presence and/or concentration of an analyte in a sample include normalized calibration information relating output signal or signals the device generates in response to the analyte concentration of the sample to previously determined reference sample analyte concentrations. The measurement devices use this normalized calibration information to relate one or more output signals from an electrochemical or optical analysis of a sample to the presence and/or concentration of one or more analytes in the sample. The normalized calibration information includes a normalization relationship to normalize output signals measured by the measurement device of the biosensor system and at least one normalized reference correlation relating normalized output signals to reference sample analyte concentrations.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: May 1, 2018
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventor: Huan-Ping Wu
  • Patent number: 9949672
    Abstract: Embodiments of the invention provide apparatus, systems and methods wherein pre-event and post-event analyte concentration readings associated with an event are collected and processed to determine a numerical delta. The numerical delta may be displayed on a visual display to aid in a ready determination of the affect that the event (alone or in combination with medication and/or insulin dosages) had on the analyte concentration levels. Medication and/or insulin dosages may be displayed alongside the numerical delta to gauge immediate relationships between numerical delta, dosage and/or an associated event. Apparatus and systems for calculating and displaying the numerical delta are described, as are other aspects.
    Type: Grant
    Filed: December 8, 2010
    Date of Patent: April 24, 2018
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventors: David A. Simmons, Jeffery S. Reynolds, Paul M. Ripley, Stanley A. Telson
  • Patent number: 9944725
    Abstract: A non-leaching mediator may include a polymer having a polymeric backbone, and a plurality of phenothiazine groups bonded to the polymeric backbone. The plurality of phenothiazine groups may include at least one of a phenothiazine group having the general formula (IV): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded, and a phenothiazine group having the general formula (V): and salts thereof, where n is about 9 and “R” represents the polymeric backbone to which the phenothiazine group is bonded.
    Type: Grant
    Filed: October 26, 2016
    Date of Patent: April 17, 2018
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventors: Jiangfeng Fei, William Chiang, Frank Kerrigan, Stuart Green, Craig Robson, Howard Easterfield
  • Patent number: 9939406
    Abstract: A biosensor has an underfill detection system that determines whether a sample of a biological fluid is large enough for an analysis of one or more analytes. The underfill detection system applies an excitation signal to the sample, which generates an output signal in response to the excitation signal. The underfill detection system switches the amplitude of the excitation signal. The transition of the excitation signal to a different amplitude changes the output signal when the sample is not large enough for an accurate and/or precise analysis. The underfill detection system measures and compares the output signal with one or more underfill thresholds to determine whether an underfill condition exists.
    Type: Grant
    Filed: February 2, 2015
    Date of Patent: April 10, 2018
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventors: Huan-Ping Wu, Christine D. Nelson
  • Patent number: 9933385
    Abstract: A method of distinguishing a control solution from a sample in an electrochemical test sensor is performed. The method includes adding a control marker to the control solution. The control solution includes the control marker and analyte. The test sensor includes working and counter electrodes, and a reagent. A potential is applied to the test sensor to oxidize the control marker and the analyte. The resulting electrical current is measured. A potential is applied to the test sensor lower than the other potential in which the potential is sufficient to oxidize the analyte and not the control marker. The resulting electrical current is measured. Determining whether a control solution or a sample is present based on the measured electrical currents. To increase the measured current, a salt may be added to the control solution in an amount sufficient to increase the electrical current by at least 5% as compared to a control solution in the absence of a salt.
    Type: Grant
    Filed: September 19, 2014
    Date of Patent: April 3, 2018
    Assignee: ASCENSIA DIABETES CARE HOLDINGS AG
    Inventors: Jing Lin, Fu Hsiung Tsai, Huan-Ping Wu, Nicole D Ellis, Henry C Arndt
  • Patent number: 9933441
    Abstract: Error may be introduced into an analysis by both the biosensor system used to perform the analysis and by errors in the output signal measured by the measurement device of the biosensor. For a reference sample, system error may be determined through the determination of relative error. However, during an analysis of a test sample with the measurement device of the biosensor system, true relative error cannot be known. A pseudo-reference concentration determined during the analysis may be used as a substitute for true relative error. The closer the analysis-determined pseudo-reference analyte concentration is to the reference analyte concentration of the test sample, the more accurate and/or precise the analyte concentration determined by the measurement device using an anchor parameter during compensation. The present invention provides an improvement in the accuracy and/or precision of the analysis determined pseudo-reference concentration through progressive approximation.
    Type: Grant
    Filed: March 11, 2014
    Date of Patent: April 3, 2018
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventor: Huan-Ping Wu
  • Patent number: 9921208
    Abstract: A biosensor meter (10a) is provided for determining an analyte concentration in a fluid, such as glucose in blood. The biosensor meter includes a USB port (14a) having a first data signal port terminal (32d?), and a detection circuit (50a) including a first input terminal and an output terminal. The first input terminal of the detection circuit (50a) is coupled to the first data signal port terminal (32d?). The detection circuit (50a) provides at the output terminal a first output signal when a current sensed at the first input terminal is greater than or equal to a first predetermined amount, and a second output signal when the current sensed at the first input terminal is less than the first predetermined amount.
    Type: Grant
    Filed: March 5, 2013
    Date of Patent: March 20, 2018
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventor: Igor Gofman
  • Patent number: 9877677
    Abstract: An integrated-testing system includes a meter, a lancing device and a storage case. The meter includes a housing, a display and a processor. The storage case holds the meter and the lancing device in a relatively fixed position to each other. The meter and the lancing device are maintained in the storage case in the relatively fixed position until a fluid sample is desired, at which time a first portion of the lancing device is advanced to a position external to the storage case to obtain the fluid sample and a second portion of the lancing device remains relatively fixed in the storage case while the fluid sample is obtained.
    Type: Grant
    Filed: January 14, 2015
    Date of Patent: January 30, 2018
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventor: Steven C. Charlton
  • Patent number: 9874481
    Abstract: Methods and systems accurately determine an analyte concentration in a fluid sample. In an example embodiment, a receiving port receives a test sensor. The test sensor includes a fluid-receiving area for receiving a fluid sample. The fluid-receiving area contains a reagent that produces a measurable reaction with an analyte in the fluid sample. The test sensor has a test-sensor temperature and the reagent has a reagent temperature. A measurement system measures the reaction between the reagent and the analyte. A temperature-measuring system measures the test sensor temperature when the test sensor is received into the receiving port. A concentration of the analyte in the fluid sample is determined according to the measurement of the reaction and the measurement of the test sensor temperature. A diagnostic system determines an accuracy of the temperature-measuring system. The calculation of the analyte concentration may be adjusted according to the accuracy of temperature-measuring system.
    Type: Grant
    Filed: June 30, 2014
    Date of Patent: January 23, 2018
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventors: Narasinha Parasnis, Hoi-Cheong Steve Sun, Mu Wu
  • Patent number: 9874536
    Abstract: An electrochemical test sensor for detecting the concentration of an analyte in a fluid sample. The electrochemical test sensor includes a housing that has a first end and a second opposing end. The housing includes an opening at the first end to receive a fluid test sample. An electrode assembly includes a substrate, a working electrode, a counter electrode and a reagent. The substrate has a first surface and an opposing second surface. The working electrode is disposed on the first surface of the substrate, and the counter electrode is disposed on the second surface of the substrate. The electrode assembly is positioned within the housing to define a reaction channel. The electrochemical test sensor may be used with a removable lancet mechanism or integrated within a lancet mechanism to form one integral unit.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: January 23, 2018
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventors: Yuan Wang, Raeann Gifford, Hualin Jiang, Jeffery S. Reynolds, Jiangfeng Fei
  • Patent number: 9851261
    Abstract: A system and method for rapidly determining ambient temperature in a fluid-analyte meter. The meter includes a housing defining an interior space and an area for receiving a fluid sample. A processor and a first temperature sensor are disposed within the interior space of said the housing. A second temperature sensor is disposed on the housing. One or more processors are configured to determine a first temperature value from temperature data received from the first temperature sensor. The processor(s) are also configured to apply a variable current to a temperature-adjustment source such that the second temperature sensor is adjusted to a predetermined steady-state temperature value different from the first temperature value. The processor(s) are further configured to determine an ambient temperature of an exterior space of the housing based on the applied variable current, pre-determined steady-state temperature, and received first temperature values.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: December 26, 2017
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventor: Mu Wu
  • Patent number: 9846136
    Abstract: Biosensor systems including a measurement device and test sensors including at least three independently addressable electrodes, with at least two of the electrodes being substantially chemically isolated are disclosed. One or more working electrodes may be combined with two or more counter electrodes. The two or more counter electrodes may operate at different potentials to provide for multi-analyte electrochemical analysis. Analysis methods are provided to perform multi-analyte electrochemical analysis and test sensors are provided having resistance to chemical mixing between secondary analysis regions.
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: December 19, 2017
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventors: Huan-Ping Wu, Weiping Zhong, Joseph E. Perry, Eric Maurer, Sung-Kwon Jung
  • Patent number: 9835582
    Abstract: A sensor system, device, and methods for determining the concentration of an analyte in a sample is described. Gated voltammetric pulse sequences including multiple duty cycles of sequential excitations and relaxations may provide a shorter analysis time and/or improve the accuracy and/or precision of the analysis. The disclosed pulse sequences may reduce analysis errors arising from the hematocrit effect, variance in cap-gap volumes, non-steady-state conditions, mediator background, a single set of calibration constants, under-fill, and changes in the active ionizing agent content of the sensor strip.
    Type: Grant
    Filed: July 10, 2015
    Date of Patent: December 5, 2017
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventor: Huan-Ping Wu
  • Patent number: 9829459
    Abstract: A method of depositing reagent on an electrochemical test sensor adapted to determine information relating to an analyte includes providing a base and forming an electrode pattern on the base. The method further includes depositing the reagent on at least the electrode pattern using a reagent-dispensing system. The reagent-dispensing system applies mechanical force to the reagent in the reagent-dispensing system to assist in providing a wet reagent droplet on at least the electrode pattern.
    Type: Grant
    Filed: November 11, 2013
    Date of Patent: November 28, 2017
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventors: Boru Zhu, Herbert Henley, Jr.
  • Patent number: 9803228
    Abstract: A method of making an electrochemical sensor strip that includes: depositing a first electrode on a base; depositing a second electrode on the base; applying a first layer onto the first electrode; and applying a second layer onto the second electrode. The first layer includes an oxidoreductase and a mediator. The second layer includes a soluble redox species.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: October 31, 2017
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventors: Huan-Ping Wu, Greg P. Beer, Christina Blaschke
  • Patent number: 9784706
    Abstract: The present invention relates to systems, methods, and devices for determining the concentration of an analyte in a sample. The use of linear, cyclic, or acyclic voltammetric scans and/or semi-integral, derivative, or semi-derivative data treatment may provide for increased accuracy when determining the concentration of an analyte in a sample. Hematocrit compensation in combination with the data treatments may reduce the hematocrit effect with regard to a glucose analysis in whole blood. In another aspect, fast scan rates may reduce the hematocrit effect.
    Type: Grant
    Filed: September 24, 2014
    Date of Patent: October 10, 2017
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventor: Huan-Ping Wu
  • Patent number: 9775806
    Abstract: A biosensor system determines analyte concentration from an output signal generated from a light-identifiable species or a redox reaction of the analyte. The biosensor system compensates at least 50% of the total error in the output signal with a primary function and may compensate a portion of the residual error with at least one residual function. A segmented signal processing (SSP) function may serve as the primary function, first residual function, or second residual function. Preferably, when the SSP function serves as the first residual function, the SSP function compensates at least 50% of the residual error remaining after primary compensation. Preferably, when the SSP function serves as the second residual function, the SSP function compensates at least 50% of the residual error remaining after primary and first residual compensation. The error compensation provided by the primary, first residual, and second residual functions may be adjusted with function weighing coefficients.
    Type: Grant
    Filed: September 20, 2012
    Date of Patent: October 3, 2017
    Assignee: Ascensia Diabetes Care Holdings AG
    Inventor: Huan-Ping Wu
  • Publication number: 20170277852
    Abstract: A system managing health-related issues (e.g., diabetes) includes a measurement device to measure a health characteristic and a processing device communicatively coupled to the measurement device. The processing device receives the measurement from the measurement device. The processing device includes at least one memory device, a processor, and a user interface. The at least one memory device stores the one or more measurements and computer-readable instructions for a healthcare application. The processor executes the healthcare application. The health care application displays and receives, via the user interface, supplemental health data in association with the one or more measurements. The healthcare application allows a user to input the supplemental data according to adherence burst prompting, measurement and logging prescription, retroactive logging, and/or data display with an electronic calendar.
    Type: Application
    Filed: September 8, 2015
    Publication date: September 28, 2017
    Applicant: Ascensia Diabetes Care Holdings AG
    Inventors: Jeffery S. Reynolds, Kuen Chang, Amy Lynn Schwartz, Aaron Ferber